October 11, 2022•Publication
Gate MRI’s Head of Vaccine Development, Alex Schmidt, joins a panel of international experts on a recent consensus statement for the development of TB vaccines in those with HIV. The paper outlines recommendations for vaccine developers on which vaccines, patient populations, and efficacy endpoints to prioritize when investigating a TB vaccine in individuals with HIV as well as ethical and regulatory factors to consider.
September 1, 2022•Publication
August 17, 2022•Press Release
The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) collaboration announced today the execution of a joint development agreement (JDA) — among Janssen Pharmaceutica NV, Otsuka, TB Alliance and the Bill & Melinda Gates Medical Research Institute — supporting the progression of two investigational tuberculosis (TB) combination treatment regimens into phase 2 clinical development.
August 5, 2022•News Article
Gates MRI's Head of Therapeutics Development, Charles Wells, gave an interview with News Medical in which he discussed our current research into tuberculosis, the World Health Organization's new guidelines for TB care, and what inspired his career. He also spoke about Gates MRI's novel potential vaccine interventions and how we're supporting future innovative approaches to TB treatment.
August 1, 2022•News Article
Gates MRI's CEO Emilio Emini conducted a Q&A with MassBio and shared how Gates MRI is developing biomedical interventions to address global health concerns for those in the greatest need.
April 5, 2022•News Article
Gates MRI’s Head of Vaccine Development, Alex Schmidt, discussed Gates MRI’s tuberculosis epidemiology study. He referred to the study’s role in setting the stage for a potential Phase 3 efficacy trial for Gates MRI’s investigational tuberculosis vaccine.
March 24, 2022•News Article, Written by Gates MRI
Gates MRI’s Head of Therapeutics Development, Charles Wells, wrote a post for Medicines Patent Pool outlining public health challenges stemming from tuberculosis. He also highlighted how partnerships can play a key role in helping to contribute to ending the TB epidemic by 2030.
March 22, 2022•Podcast
Gates MRI’s CEO Emilio Emini gave an in-depth interview to the Progress, Potential, and Possibilities podcast on immunology, vaccinology, and his career in public health. He also provided an overview of Gates MRI’s research priorities and discussed a call-to-action for preparedness ahead of the next pandemic.
March 21, 2022•Publication, Written by Gates MRI
Gates MRI’s Exploratory Biomarker Leader, Nicole Frahm, and Clinical Development Leader, David Holtzman, contributed to the important review of new TB treatment monitoring biomarkers with colleagues from UNITE4TB and FIND — the global alliance for diagnostics.
March 16, 2022•News Article
Gates MRI’s Clinical Development Leader, Alemnew Dagnew, gave an interview about the latest tuberculosis vaccine study at Gates MRI and the future of tuberculosis worldwide.
November 5, 2021•Publication
Gates MRI’s Head of Bioassay Development and Operations, Joleen T. White, published research that provides a hypothetical case study to present an immunogenicity risk assessment for a multi-specific therapeutic as part of an Investigational New Drug (IND) application.
October 1, 2021•Publication
September 15, 2021•Publication
Gates MRI’s Chief Medical Officer and Head of Development, Michael Dunne; Program Lead Mohamed Bassyouni; Head of Global Regulatory Strategy & Operations, Taryn Rogalski-Salter; Head of Translational Discovery, Jared Silverman; and Program Leads Jeroen Medema and Mohamed Bassiouni investigated whether rivaroxaban, a direct oral anticoagulant factor Xa inhibitor, would reduce coronavirus disease 2019 (COVID-19) progression.
